Clinical Trials Logo

Filter by:
NCT ID: NCT04871932 Recruiting - Clinical trials for Immune System and Related Disorders

COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics

Start date: February 1, 2021
Phase:
Study type: Observational

In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell heterogeneity in multicellular organisms. Analyzing the changes in the expression profile of the cell transcriptome at the single-cell level can clearly show the changes in the trajectory of individual cells, reveal new cell types, and discover the potential functions of immune cells. Therefore, this study intends to recruit healthy adults and use multi-omics techniques such as single-cell sequencing to systematically classify the peripheral blood mononuclear cells of healthy adults to provide a basis for further disease-related research.

NCT ID: NCT04871880 Recruiting - Clinical trials for Metabolic Associated Fatty Liver Disease

Lifestyle Modification for MAFLD Based on TTM

Start date: May 17, 2020
Phase: N/A
Study type: Interventional

Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle. Thus, this study aims at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.

NCT ID: NCT04871464 Recruiting - Parkinson Disease Clinical Trials

Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease

Start date: November 11, 2021
Phase: Phase 4
Study type: Interventional

This study is a multicenter randomized double-blind placebo-controlled study. The research content is 1. The improvement effect of Bifidobacterium triple viable capsules(BIFICO) on motor symptoms and constipation and sleep in mild to moderate Parkinson's disease and the safety of the study; 2. the mechanism of the improvement effect of intestinal microecological changes on motor and constipation symptoms in mild to moderate Parkinson's disease.

NCT ID: NCT04871334 Recruiting - Advanced Melanoma Clinical Trials

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Start date: February 7, 2021
Phase: Phase 1
Study type: Interventional

This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety, tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and urothelial carcinoma. This study consists of two parts (Part A and Part B). Part A was a dose escalation study, and Part B was a dose expansion study.

NCT ID: NCT04870983 Recruiting - Clinical trials for Sepsis-Associated Encephalopathy

The Dynamic Change of MMN in Patients With Sepsis Associated Encephalopathy

Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Sepsis-associated encephalopathy (SAE), is one of the most common organ dysfunction during the acute phase in sepsis and septic shock. Electroencephalogram (EEG) and auditory evoked potentials (AEPs), which reflect different aspects of brain function, are the most commonly used neurophysiological indices to detect acute brain dysfunction in critically ill patients including sepsis and septic shock. AEPs show the systemic responsiveness of the central nervous to auditory stimuli, so they can be considered a direct measure of brain responsiveness. Mismatch negativity (MMN) is a change-specific component of ERPs, which elicited by a deviant stimulus occurring in a sequence of repetitive stimuli. This component is thought to represent the automatic and unconscious detection of acoustic changes which requires good perceptual discriminative capacity and iconic memory. The peaks of MMN appear at 100 ~ 250 ms from deviant stimulus onset; with increasing magnitude of stimulus change, the peak latency of MMN was shortened and the amplitude increased. Since MMN can be elicited even in the absence of attention, subjects do not need to actively participate. The MMN has been extensively demonstrated to be used in the prediction of awakening in comatose patients for various reasons, and also has been reported to predict awakening in deeply sedated critically ill patients recently. However, it remains unclear whether SAE affects MMN in amplitude and latency that reflects cognitive processing of the auditory information. Patients with sepsis and septic shock who met the inclusion criteria were screened daily on the CAM-ICU scale, and those with positive CAM-ICU were diagnosed with SAE.All patients were tested for event-evoked potentials on Day 1 and Day 3 after inclusion and were followed up to Day 28 after discharge. The investigators intend to observe the dynamic change of MMN amplitude and latency between SAE and non-SAE groups. Logic regression analysis was used to determine whether the change of MMN was a predictor of SAE.

NCT ID: NCT04870697 Recruiting - Childhood Cancer Clinical Trials

Acceptance and Commitment Therapy for Parents of Children With Cancer

ACT
Start date: June 28, 2021
Phase: N/A
Study type: Interventional

The current study aims to develop a theoretically driven ACT intervention and examine its effects among parents of children with cancer. The objectives are: 1. To examine the effects of ACT intervention on parental QOL and psychological distress (symptoms of anxiety, depression and stress) in parents of children with cancer. 2. To examine the effects of ACT intervention on parental negative experience, experiential avoidance and psychological flexibility in parents of children with cancer. 3. To examine the effects of ACT intervention on psychological adjustment of children with cancer.

NCT ID: NCT04869475 Recruiting - Clinical trials for Refractory Solid Tumors

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in those patients will be evaluated.

NCT ID: NCT04869332 Recruiting - Clinical trials for Femoral Neck Fractures

Three Cancellous Screws Versus Four Cancellous Screws for Femoral Neck Fixation

Start date: April 8, 2021
Phase: N/A
Study type: Interventional

This study is a prospective randomized controlled clinical study. Patients with femoral neck fracture (AO classification 31-B) will be randomly divided into three-screw fixation group and four-screw fixation group. The internal fixation failure rate (IFFR) and functional outcomes of the two groups will be compared and the patients will be followed up to 2 years after surgery.

NCT ID: NCT04868162 Recruiting - Clinical trials for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Start date: April 23, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

NCT ID: NCT04867330 Recruiting - Clinical trials for Immune Checkpoint Inhibitor

Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data were collected from non-Chinese areas. Like nasopharyngeal carcinoma (NPC), oropharyngeal carcinoma may have different biological behavior and relationship with HPV infection. So the investigators studied whether toxicities reducing treatment with reduced radiation dose and omitted concurrent chemotherapy after good response to induction chemotherapy would maintain survival outcomes while improving tolerability for patients with HPV-positive oropharyngeal carcinoma. Immune checkpoint inhibitors (ICIs) have proved to improve outcomes of head and neck cancers including EBV-related NPC. Oropharyngeal carcinoma was considered to be similar with NPC in terms of immune environment. So we added anti-PD-1 antibody Toripalimab to induction chemotherapy in order to achieve better response rates to receive de-escalation chemoradiotherapy followed.